A Study to Evaluate ALN-2232 in Participants With Obesity
Recruiting now Phase 1/2 NCT07463846
Run by Alnylam Pharmaceuticals · for 18 to 65 · All sexes
What this study is about
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Who can join (things the study team will check)
✅ You may be able to join if…
- Has a body mass index (BMI) of ≥30 kg/m\^2 and <40 kg/m\^2
- Has a hemoglobin A1c (HbA1c) <6.5%
🚫 You may not be able to join if…
- Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
- Receiving therapies for chronic weight management or antidiabetic medications Note: other protocol defined inclusion/exclusion criteria apply
Where this trial is running
- Clinical Trial Site, Mount Royal, Canada
Who to contact
Alnylam Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07463846.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.